| Zacks Company Profile for Enzo Biochem, Inc. (ENZ : NYSE) |
|
|
| |
| • Company Description |
| Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Number of Employees: 514 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $2.40 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 65,971 shares |
| Shares Outstanding: 48.71 (millions) |
| Market Capitalization: $116.90 (millions) |
| Beta: 0.80 |
| 52 Week High: $4.15 |
| 52 Week Low: $2.23 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-16.38% |
-5.81% |
| 12 Week |
-27.71% |
-20.52% |
| Year To Date |
-25.23% |
-8.65% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
527 Madison Ave.
-
New York,NY 10022
USA |
ph: 212-583-0100
fax: 212-679-7999 |
ir@enzo.com |
http://www.enzo.com |
|
|
| |
| • General Corporate Information |
Officers
Elazar Rabbani - Chief Executive Officer;Chairman of Board of Direc
Barry W. Weiner - President and Treasurer
David Bench - Chief Financial Officer; Principal Accounting Of
Dov Perlysky - Director
Mary Tagliaferri - Director
|
|
Peer Information
Enzo Biochem, Inc. (CORR.)
Enzo Biochem, Inc. (RSPI)
Enzo Biochem, Inc. (CGXP)
Enzo Biochem, Inc. (BGEN)
Enzo Biochem, Inc. (GTBP)
Enzo Biochem, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 294100102
SIC: 8071
|
|
Fiscal Year
Fiscal Year End: July
Last Reported Quarter: 01/01/22
Next Expected EPS Date: 06/08/22
|
|
Share - Related Items
Shares Outstanding: 48.71
Most Recent Split Date: 10.00 (1.05:1)
Beta: 0.80
Market Capitalization: $116.90 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: 0.00 |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 06/08/22 |
|
|
|
| |
